Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.570 -0.100 (-1.30%)
Streaming Delayed Price Updated: 12:36 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
News headline image
Expert Ratings For Arcturus Therapeutics ↗
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed ... 
Via Benzinga
News headline image
Analyst Ratings For Arcturus Therapeutics ↗
Analysts have provided the following ratings for Arcturus Therapeutics (NASDAQ: 
Via Benzinga
News headline image
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
News headline image
31 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Leadership Appointments
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
92 Biggest Movers From Friday ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
News headline image
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT ↗
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal... 
Via Benzinga
News headline image
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83 ↗
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
News headline image
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an... 
Via Benzinga
News headline image
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Mid-Day Market Update: ExOne Rises Following Acquisition News; LifeStance Health Shares Plummet ↗
Midway through trading Thursday, the Dow traded down 0.32% to 35,369.96 while the NASDAQ rose 0.01% to 14,766.11. The S&P also fell, dropping 0.10% to 4,443.23. The U.S. has... 
Via Benzinga
Topics Stocks
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 ↗
Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd 
Via Benzinga
News headline image
Arcturus Stock, A Covid Play, Flashes Vital Signs ↗
A Relative Strength Rating upgrade for Alcobra shows improving technical performance. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 ↗
Upgrades According to Barclays, the prior rating for Albertsons Companies Inc (NYSE: 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.